Switzerland Approves SCENESSE® Reimbursement
Clinuvel Pharmaceuticals Limited today announced that SCENESSE® (afamelanotide 16mg implant) has been accepted by two leading health insurers in Switzerland for full reimbursement for the prophylactic treatment of patients with erythropoietic protoporphyria (EPP).
SCENESSE® can be supplied with immediate effect to physicians who treat approximately 50 EPP patients in Switzerland. The costs of supply will be covered in full by the insurance companies. This is the second country where SCENESSE® is fully reimbursed for EPP. The drug has been available on prescription in Italy since 2010. Both countries have allowed supply of the drug under specific laws prior to formal European approval.
It is our hope that the FDA will approve the treatment for US patients after the Phase III trial. We again want to thank the patients who have volunteered.
Remember ........ Research is the key to your cure!